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Background: Renal toxicity is a clinical problem that affects 28 − 42% of patients undergoing treatment with
cisplatin. Renal toxicity can be minimized by high volume hydration with mannitol diuresis. Recent reports have shown
that cisplatin induces depletion of Mg and that Mg supplementation can reduce renal toxicity. We hypothesized that
Mg infusion combined with low volume hydration may not be sufficient to overcome cisplatin-induced renal toxicity.
Methods: In total, 85 patients with lung cancer receiving their first cycle of cisplatin-based chemotherapy at the Osaka
City University Hospital were classified into three groups: those administered high volume hydration without Mg infusion
(high-volume Mg-), high volume hydration with Mg infusion (high-volume Mg+), and with low volume hydration with
Mg infusion (low-volume Mg+). Serum creatinine (sCr) and creatinine clearance (CrCl) were examined before and after
treatment with cisplatin. Multivariable analysis was carried out to identify the most important contributing factors.
Results: There were no significant differences in pre-treatment sCr levels or CrCl between groups. In the high-volume
Mg- group, post-treatment sCr significantly increased compared with pre-treatment levels, while post-CrCl significantly
decreased compared with pre-treatment CrCl (p < 0.001 and p < 0.001, respectively). In the high-volume Mg+ group,
there was no significant difference between pre- and post-treatment levels of sCr, or between pre- and post-treatment
CrCl (p = 0.118 and p = 0.254, respectively). In the low-volume Mg+ group, there was a trend towards increased sCr
levels and decreased CrCl after treatment (p = 0.068 and p = 0.055, respectively). Multivariate analysis revealed that the
absence of Mg infusion and low-volume hydration were both independent factors for decreased CrCl (p < 0.001 and
p = 0.001, respectively).
Conclusions: High-volume hydration and Mg infusion reduces the renal toxicity induced by cisplatin. A low-volume
Mg+ regimen may be considered for patients with adequate renal function. Trial Registration: Observational Study
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The mortality rate associated with lung cancer is increasing
worldwide. In fact, lung cancer (along with tracheal and
bronchial cancers) was responsible for 1.5 million (2.7%)
deaths in 2011, compared with 1.2 million (2.2%) deaths in
2000, according to the World Health Organization. In
more than 60% of patients with lung cancer, particularly
those with non-small cell lung cancer (NSCLC), the
cancer is inoperable at the time of diagnosis and requires
chemotherapy [1].
Cisplatin is one of the most important components of
standard therapies for lung cancer and is also an effective
adjuvant for chemotherapy and chemoradiotherapy [2].
Renal toxicity is a well-known adverse effect of cisplatin
treatment, which limits its use. Despite intensive prophy-
lactic measures, renal toxicity still affects a large proportion
of patients treated with cisplatin, and a significant decrease
in glomerular filtration rate is commonly observed
during treatment [3]. In 1977, Cvitkovic et al. reported
that cisplatin-induced renal toxicity could be avoided with
substantial hydration and mannitol-induced diuresis [4].
Subsequently, clinical trials were initiated in several
types of cancers, including epidermoid carcinoma, ovarian
adenocarcinoma, germ cell tumors of the testis, and meta-
static melanoma [5,6]. Hayes et al. reported about patients
who had been pre-hydrated intravenously with 2,000 ml of
5% glucose in one-half normal saline over 12 h, and
post-hydrated with 1,200 ml of one-half normal saline
over 6 h. Mannitol was infused (50 ml of 25% mannitol)
as an intravenous bolus just before the administration of
cisplatin, and was continuously infused (300 ml of 20%
mannitol) for 6 h after the administration of cisplatin [6].
Even if cisplatin was approved in 1984 for use in Europe
and the United States, nephrotoxic damage still affects
28 − 42% of patients treated with cisplatin [7].
To date, a number of studies have investigated strategies
for prevention of cisplatin-induced renal toxicity. As free
cisplatin causes renal toxicity, shortening the free cisplatin
and renal tubular contact time is important to reduce its
nephrotoxicity [8]. As more than 90% of free cisplatin
binds to plasma proteins within 4 h, hydration within that
time after initiating treatment is a critical factor in
reducing toxicity [8]. In addition, previous reports have
demonstrated that cisplatin-induced Mg depletion may
occur in some patients [9]. Willox et al. revealed that
supplementation with 16 mEq Mg was beneficial in
reducing renal tubular damage in patients with testicular
cancer receiving cisplatin [10], while Bodnar et al.
demonstrated that 40 mEq Mg supplementation had
nephroprotective effects during chemotherapy with cisplatin
in patients with epithelial ovarian cancer [7]. Muraki et al.
showed that hydration with 8 mEq Mg and mannitol
without furosemide prevents the nephrotoxicity induced
by cisplatin and pemetrexed in patients with advancedNSCLC [11]. Hirai, et al. also showed that 20 mEq Mg
supplementation may be beneficial in preventing cisplatin-
induced nephrotoxicity in patients with esophageal or
hypopharyngeal cancer [12]. Yoshida et al. reported that
8 mEq Mg preloading before cisplatin administration
significantly reduced cisplatin-induced nephrotoxicity in
496 patients with thoracic malignancies [13]. Therefore,
Mg supplementation, in addition to hydration, may also
reduce the renal toxicity induced by cisplatin. Therefore,
Mg supplementation is being considered an option for
cisplatin-based chemotherapy. Prospective studies since
2007 have examined the use of low-volume hydration in
combination with Mg supplementation. Tiseo, et al.
demonstrated that low-volume hydration with 16 mEq Mg
supplementation in cisplatin-based chemotherapy led to no
increase in creatinine in only 35.3% of patients [14].
Hotta et al. reported that low-volume hydration (2,500 ml)
with 4 mEq Mg supplementation before and after cisplatin
administration was associated with slightly worse renal
toxicity during all cycles of chemotherapy, without
significance [15]. Horinouchi et al. examined the safety of
low-volume hydration (1,550 − 2,050 ml) with 8 mEq Mg
supplementation; however, renal function during all courses
of cisplatin administration was slightly worse [2]. However,
few studies have compared the renal toxicities associated
with treatment using high-volume hydration with Mg
supplementation to those associated with treatment using
low-volume hydration with Mg supplementation. We
hypothesized that Mg infusion may not be sufficient to
overcome the renal toxicity caused by cisplatin during
low-volume hydration. Therefore, we performed a historical
prospective cohort study wherein patients were classified
into three groups: high-volume hydration without Mg
infusion, high-volume hydration with Mg infusion, and
low-volume hydration with Mg infusion.
Methods
Patients
This study was reported according to the STROBE guide-
lines [16]. The chemotherapy procedure was explained and
informed consent was obtained from all patients before
treatment. The Mg/hydration protocols were approved by
the Institutional Review Board (No. 1402) of Osaka City
University Hospital in accordance with the Declaration of
Helsinki.
The renal toxicity in patients with lung cancer receiving
their first cycle of cisplatin-based chemotherapy at the
Osaka City University Hospital between December 2011
and October 2013 were included in the present study.
Patients were placed into three groups, and renal toxicity
was compared before and after cisplatin-based chemother-
apy. In our hospital, until December 2012, we performed
conventional high-volume hydration without Mg infu-
sion in patients undergoing cisplatin-based chemotherapy
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administration of Mg sulfate during the pre-hydration
stage (high-volume Mg+). Subsequently, the new
low-volume hydration with Mg infusion regimen was
initiated in July 2013 (low-volume Mg+). We investigated
patient characteristics including age, sex, body surface area,
performance status, stage, histology, serum hemoglobin,
serum albumin, serum creatinine (sCr), creatinine clear-
ance (CrCl), cisplatin dose, regular use of non-steroid
anti-inflammatory medicines, regular use of Mg-containing
medications for purgative, and combined anticancer agents.
Treatments
All patients received combination chemotherapy of
cisplatin and another cytotoxic agent (i.e. vinorelbine,
pemetrexed, irinotecan, etoposide, gemcitabine, S-1,
amrubicin, or docetaxel). Table 1 shows an example of theTable 1 An example of the chemotherapy hydration regimen
High-volume hydration Mg- Hig
ml
Day 1 N.S. 50 N.S
Antiemetics
Granisetoron 3 mg 100 Gra
Dexamethasone 6.6 mg 2 Dex




Pre-hydration N.S. 500 N.S
1/4 saline solution 500 1/4
Mg
Diuresis 20%
Cisplatin N.S. with cisplatin 300 N.S
Post-hydration N.S. 500 N.S
Diuresis 20% Mannitol 300
Post-hydration 1/4 saline solution 500 1/4
Diuresis 20% Mannitol 300 20%
Frosemide 20 mg 2 Fro
Oral hydration 0
Day 2,3 N.S. 50 N.S
Antiemetics Granisetoron 3 mg 100 Gra
Dexamethasone 6.6 mg 2 Dex
Hydration 1/4 saline solution 500 1/4
Diuresis 20% Mannitol 300 20%
Oral hydration 0
Total infusion Day 1 3,550 Day
Day 2,3 950 Day
N.S., normal saline.chemotherapy hydration regimen in each group. In the
high-volume Mg- and high-volume Mg+ groups, patients
were administered a total of 3,550 ml of electrolyte-
containing solutions that contained normal saline and
one-quarter saline solution Soldem 3A (Terumo, Tokyo,
Japan) on day 1 and 950 ml of the solutions on days 2 and
3. A total of 600 ml of 20% mannitol and furosemide
(20 mg) was administered as enforced diuresis on day 1,
and 300 ml of 20% mannitol was administered on days 2
and 3. Antiemetic agents (dexamethasone [6.6 mg] and
granisetron [3 mg]) were infused on days 1–3. Cisplatin,
which was dissolved in 300 ml of normal saline solution,
was infused over 90 min. In the low-volume Mg+
group, patients were administered a total of 2,200 ml of
electrolyte-containing solutions on day 1 with no infusions
on days 2 and 3; instead, they were administered 2,000 ml
of water per os on day 1 and 1,000 ml of water on days 2for each group
h-volume hydration Mg+ Low-volume hydration Mg+
ml ml
. 50 N.S. 50
N.S. 100
nisetoron 3 mg 100 Fosaprepitant meglumine
150 mg
amethasone 6.6 mg 2 N.S. 50
Palonosetoron 0.75 mg 5
Dexamethasone 9.9 mg 2
. with other
otoxic agent
500 N.S. with other cytotoxic agent 100
. 500 1/4 saline solution 500
saline solution 500 MgSO4 8 mEq
SO4 8 mEq
Mannitol 300 20% Mannitol 300
. with cisplatin 300 N.S. with cisplatin 100
. 500 N.S. 500
saline solution 500 1/4 saline solution 500
Mannitol 300
semide 20 mg 2
0 2,000
. 50
nisetoron 3 mg 100




1 3,550 Day 1 2,200
2,3 950 Day 2,3 0
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before cisplatin administration on day 1. Antiemetic
agents (fosaprepitant meglumine [150 mg], dexametha-
sone [6.6 mg], and palonosetron [0.75 mg]) were
administered on day 1. Cisplatin, which was dissolved
in 100 ml of normal saline solution, was administered over
45 min. In the high- and low-volume Mg+ groups, Mg
sulfate was administered before cisplatin in one-quarter
saline solution. The dose of Mg sulfate was 8 mEq based
on previous reports [2,11]. Blood chemistry was analyzed
twice a week during treatment. The chemotherapy
procedure was explained and informed consent was
obtained from all patients. Since this was a historical
prospective cohort study, the difference from the previous
Mg- protocol was explained to patients in high volume
Mg+ group, and the patients in low volume Mg+ group
were informed about the difference from the previous
high volume Mg+ protocol.Renal function and gastrointestinal toxicity
Changes in sCr and gastrointestinal toxicity/anorexia
were assessed using Common Terminology Criteria for
Adverse Events Version 4.0 (CTCAE v4.0). sCr was
measured just before chemotherapy (pre-sCr), twice
a week during treatment, and on the last day of the
first cycle of chemotherapy (post-sCr). CrCl was cal-
culated using the Cockcroft-Gault formula: CrCl
[ml/min] = (140 – age [years] × weight [kg]) × 0.85 [if
female]/(72 × sCr [mg/dl]). ΔsCr was calculated using
the formula: ΔsCr [mg/dl] = (sCr [mg/dl] after chemo-
therapy) – (sCr [mg/dl] before chemotherapy). ΔCrCl
was calculated using the formula: ΔCrCl [ml/min] =
(CrCl [ml/min] before chemotherapy) – (CrCl [ml/min]
after chemotherapy).Statistical analysis
Chi-square and Fisher’s exact tests were used for
categorical comparisons of data. Differences in the
means of continuous measurements were tested with
a Student’s t-test and the Mann-Whitney U test. The
paired t-test and Wilcoxon matched-pairs signed-rank test
was used for paired continuous measurements. The
influence of the following factors on changes in CrCl
were investigated on univariate analysis: age, sex, perform-
ance status, serum albumin, cisplatin dose, regular use of
non-steroid anti-inflammatory medicines, regular use of
Mg-containing purgatives, ≥grade 2 anorexia, Mg infu-
sion, and low-volume hydration. All of the factors were
then included in a multiple linear regression model to
identify contributing factors. P values < 0.05 were con-
sidered statistically significant. All statistical analyses
were performed with the statistical package Stata 12
for Windows.Results
Patient characteristics
A total of 89 patients were enrolled. Four patients whose
complications or medical histories may have affected
their renal function were excluded; these included cases of
a carcinoma of unknown primary, nephrotic syndrome,
renal cancer, and a patient who received an inadequate
amount of Mg sulfate. Eighty-one patients had lung
cancer, while the remaining had thymic and bronchial
cancers. Forty-one patients were included in the high-
volume Mg- group, 27 in the high-volume Mg+ group,
and 17 in the low-volume Mg+ group. Table 2 shows the
characteristics of the 85 eligible patients. There were no
significant differences in clinical and pathological parame-
ters between the three groups. We analyzed the number
of chemotherapy cycles and major reasons for treatment
discontinuation (Additional file 1: Table S1). In the high-
volume Mg- group, the most common event leading to
discontinuation was renal toxicity (n = 9, [22%]), followed
by generalized weakness (n = 5, [12%]). On the other hand,
in the high- and low-volume Mg+ groups, it was seen that
none and 1 patient, respectively, discontinued cisplatin
treatment due to renal toxicity. The reasons for discon-
tinuation in these groups were other adverse reactions,
switching to another regimen, and cancer progression.
Renal toxicity
Table 3 shows the maximum grade of sCr increase in
each group. In the high-volume Mg- group, the grade was
significantly higher than that in the high- and low-volume
Mg+ groups (p < 0.001 and p = 0.02, respectively). Grade 1
renal toxicity was seen in 96.3% and 88.2% of patients in
the high- and low-volume Mg+ groups, respectively. Next,
we examined the recovery of sCr and CrCl after cisplatin
treatment. Table 4 shows the comparison between
pre- and post-treatment values of sCr and CrCl in
each group. No significant differences in sCr or CrCl were
present between the three groups before treatment. In the
high-volume Mg- group, post-sCr significantly increased
compared with pre-sCr, while post-CrCl significantly
decreased compared to pre-CrCl (p < 0.001 and p < 0.001,
respectively). In the high-volume Mg+ group, there was
no significant difference between pre- and post-sCr levels
or between pre- and post-CrCl (p = 0.118 and p = 0.254,
respectively). In the low-volume Mg+ group, there was a
trend towards an increase in post-sCr compared with
pre-sCr levels, and a trend towards a decrease in
post-CrCl compared to pre-CrCl (p = 0.068 and p = 0.055,
respectively). Figure 1 shows the comparison of ΔsCr and
ΔCrCl between treatment groups. The ΔsCr in the high-
volume Mg- group (median, 0.15 mg/dl; interquartile
range, 0.06 to 0.46 mg/dl) was significantly higher
compared with ΔsCr in the high-volume Mg+ (median,
0.03 mg/dl; interquartile range, −0.03 to 0.06 mg/dl) and
Table 2 Patient characteristics
High volume hydration Mg- High volume hydration Mg+ Low volume hydration Mg+
(n = 41) (n = 27) (n = 17)
Age (year) 66 (63 to 70) 66 (57 to 70) 63 (62 to 67)
Gender Male (%) 31 (75.6) 18 (66.6) 16 (94.1)
BSA (m2) 1.7 ± 0.2 1.6 ± 0.2 1.7 ± 0.2
PS (ECOG): 0 (%) 5 (12.1) 4 (14.8) 5 (29.4)
1 (%) 36 (87.8) 23 (85.2) 12 (70.6)
Stage I (%) 0 (0) 1 (3.7) 0 (0)
II (%) 5 (12.2) 3 (11.1) 3 (17.6)
III (%) 25 (61.0) 15 (55.5) 8 (47.1)
IV (%) 9 (22.0) 7 (25.9) 6 (35.3)
Others (%) 2 (4.9) 1 (3.7) 0 (0)
Histology Adenocarcinoma (%) 17 (41.5) 13 (48.1) 11 (64.7)
Squamous cell carcinoma (%) 11 (26.8) 7 (25.9) 5 (29.4)
Small cell carcinoma (%) 9 (22.0) 6 (22.2) 1 (5.9)
Others (%) 4 (9.8) 1 (3.7) 0 (0)
Serum Hb (g/dl) 13.3 (12.0 to 14.8) 13.6 (12.8 to 14.8) 13.3 (12.7 to 14.9)
Serum Alb (g/dl) 4.0 ± 0.4 4.1 ± 0.4 3.9 ± 0.4
Cisplatin dose (mg/m2) 80 (80 to 80) 80 (75 to 80) 80 (75 to 80)
Regular use drug
NSAIDs (%) 10 (24.4) 2 (7.4) 2 (11.7)
Mg for purgative (%) 14 (34.1) 8 (29.6) 5 (29.4)
Combined anticancer agent (%)
VNB 22 (53.7) 13 (48.1) 10 (58.8)
PEM 3 (7.3) 6 (22.2) 5 (29.4)
CPT-11 3 (7.4) 1 (3.7) 0
VP-16 8 (19.5) 6 (22.2) 1 (5.9)
GEM 2 (4.9) 0 1 (5.9)
S-1 1 (2.4) 1 (3.7) 0
AMR 1 (2.4) 0 0
DTX 1 (2.4) 0 0
Continuous variables are expressed as mean ± standard deviation or median (interquartile range). Categorical variables are expressed as number (proportion).
BSA, body surface area; PS, performance status; Hb, hemogulobin; Alb, albumin; NSAIDs, non-steroid anti-Inflammatory drugs; Non-Steroidal Anti-Inflammatory
Drugs; Mg for purgative, Mg-contating medications for purgative; VNB, vinorelbine; PEM, pemetrexed; CPT-11, irinotecan; VP-16, etoposide; GEM, gemcitabine;
AMR, amurubicin; DTX, docetaxel.
Oka et al. BMC Pharmacology and Toxicology 2014, 15:70 Page 5 of 9
http://www.biomedcentral.com/2050-6511/15/70low-volume Mg+ groups (median, 0.03 mg/dl; interquar-
tile range, −0.02 to 0.08 mg/dl) (p < 0.001 and p = 0.0035,
respectively). The ΔCrCl in the high-volume Mg- group
(median, 16.29 ml/min; interquartile range, 5.96 to
28.68 ml/min) was also significantly higher than ΔCrCl in
the high-volume Mg+ (median, 1.99 ml/min; interquartile
range, −3.79 to 8.56 ml/min) and low-volume Mg+
groups (median, 3.63 ml/min; interquartile range −2.09 to
10.13 ml/min) (p < 0.001 and p = 0.0316, respectively). We
also analyzed the sCr of each group at the end of
subsequent cycles. The median values of sCr at the end of
therapy in the high-volume Mg- and low-volumeMg+ groups were significantly increased compared with
pre-sCr using the paired t-test and Wilcoxon matched-
pairs signed-rank test (p < 0.001, and p = 0.01, respectively)
(Additional file 2: Table S2).
Univariate and multivariate analyses
Table 5 shows the results of univariate and multivariate
analyses. Only Mg infusion was a good predictor in univari-
ate analysis (p < 0.001). In multivariate analysis, Mg infusion
was a significant good predictor of ΔCrCl and low-volume
hydration was a significant poor predictor of ΔCrCl
(p < 0.001 and p = 0.001, respectively).
Table 3 The maximum grade of sCr increased and anorexia in each group
Grade (n/%) High-volume hydration
Mg- (n = 41)
High-volume hydration
Mg+ (n = 27)
Low-volume hydration
Mg+ (n = 17)
P value (High Mg- vs
High Mg+)
P value (High Mg- vs
Low Mg+)
sCr
0 0 (0) 1 (3.7) 1 (5.9) <0.001 0.002
1 22 (53.6) 26 (96.3) 15 (88.2)
2 17 (41.5) 0 (0) 1 (5.9)
3 2 (4.9) 0 (0) 0 (0)
anorexia
< 2 33 (80.4) 21 (77.8) 14 (82.4) 0.787 0.592
≥ 2 8 (19.5) 6 (22.2) 3 (17.6)
The maximum grade of sCr increase was assessed using the Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0).
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We found that renal function was significantly worse
after cisplatin treatment in the high-volume Mg- group,
and it also tended to worsen in the low-volume Mg+ group.
Only the high-volume Mg+ group showed no significant
alterations in renal function after cisplatin treatment.
Multivariate analysis indicated that both the absence of
Mg infusion and low-volume hydration were independent
predictors for decreased renal function.
Mg supplementation and high-volume hydration may
protect against the renal toxicity induced by cisplatin
[7,10,11]. Although the detailed mechanism underlying
this effect is not clear, recent reports have shown that
the human organic cation transporter 2 (OCT2) is
predominantly expressed in the human kidney at the
basolateral membrane of renal proximal tubules [17].
In mice, Oct2 has been implicated in the cellular uptake
of cisplatin, and Oct1/Oct2-deficient mice are protected
from severe cisplatin-induced renal tubular damage [17].
In rats, Mg depletion may cause dehydration and up-
regulation of rat Oct2, which enhances renal accumulation
of cisplatin and subsequent acute kidney injury [18]. In
humans, a single nucleotide polymorphism in the OCT2
gene SLC22A2 (rs316019) has been associated with
reduced cisplatin-induced nephrotoxicity and decreased
gene expression [17]. In renal proximal tubule cells, the
accumulation of cisplatin from the basolateral side is
significantly greater than that from the apical side [19].Table 4 The comparison between pre and post sCr, and CrCl
Pre sCr Post sCr
(mg/dl) (mg/dl)
High-volume hydration Mg- 0.75 0.92
(0.64 to 0.92) (0.79 to 1.21)
High-volume hydration Mg+ 0.71 0.71
(0.58 to 0.84) (0.63 to 0.84)
Low-volume hydration Mg+ 0.72 0.73
(0.68 to 0.78) (0.70 to 0.85)
Median (interquartile range). sCr, serum creatinine; CrCl, creatinine clearance.Thus, Mg supplementation was subsequently proposed to
prevent Mg depletion and renal toxicity.
The volume of fluid for hydration is also an important
factor that affects cisplatin-induced renal toxicity [4,20,21].
To our knowledge, no previous reports have compared
renal toxicity between patients receiving high-volume Mg+
and low-volume Mg+ regimens. In the present multivariate
analysis, both the volume of hydration and Mg infusion
contributed to increased renal protection. These protocols
were based on previous reports. Recent prospective
studies have investigated low-volume hydration with
Mg supplementation using hydration volumes of
1,500 − 2,500 ml [2,14,15]. In our study, the volumes
of pre-hydration fluid administered were 1,800 ml in
the high- and 900 ml in the low-volume Mg+ groups.
However, the volumes of post-hydration fluid administered
within 4 h were almost similar between the high- and low-
volume Mg+ regimens. The difference in volume may thus
be an important factor related to the observed differences
in renal toxicity. Hydration volume is related to osmolality
and both serum and urinary concentrations of cisplatin.
The extent of cisplatin induced nephrotoxic injury is
dependent on both dose and cumulative cisplatin levels.
Since high-volume hydration reduces the concentration of
cisplatin compared to low-volume hydration, low plasma
levels of cisplatin should reduce renal accumulation and
decrease nephrotoxicity. In addition, high volume hydration
decreases osmolality of blood resulting in decreasedin each group
P value Pre CrCl Post CrCl P value
(ml/min) (ml/min)
<0.001 78.88 65.99 <0.001
(70.37 to 95.64) (48.62 to 80.13)
0.118 73.21 73.66 0.254
(67.93 to 104.61) (64.39 to 100.65)
0.068 83.59 76.99 0.055
(72.51 to103.63) (72.22 to 85.69)
Figure 1 Comparisons of ΔsCr (A) and ΔCrCl (B) between treatment groups. The box plot provides information about the median,
variability, and outliers of data distribution. The horizontal line within each box indicates the sample median. The plot consists of a box that
extends from the 25th quartile to the 75th quartile. The box lines that extend from each end to the outermost data point that falls within the
distances were computed as follows: 1st quartile +1.5 (interquartile range) and 3rd quartile +1.5 (interquartile range). Data points outside these
computed ranges were considered outliers. sCr, serum creatinine; CrCl, creatinine clearance, *P < 0.05.
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reabsorption, more diluted urine, and increased urine
output. It can thus be hypothesized that low urinary levels
of cisplatin reduce renal accumulation of cisplatin and
decrease nephrotoxicity. Therefore, the differences in
osmolality in these two protocols may be related to the
observed differences in nephrotoxicity.
One remaining question is whether Mg supplementation
will also reduce the cytotoxic effects of cisplatin on tumor
cells. Laboratory and clinical findings of Mg depletion have
been observed in patients treated with high-dose cisplatin.
Under low Mg conditions, tumor suppressors such as p21
and p27 are up-regulated, while oncogenes such as cyclins
D and E are down-regulated [22]. It has also been suggestedTable 5 The predictive factors of ΔCrCl according to univariat
Univariate analysis
Coefficient [95% CI]
Age (per 5 years) −1.15 [−3.74 to 1.43]
Female (vs male) 5.03 [−2.40 to 12.46]
PS 1 (vs PS 0) 9.16 [−1.37 to 19.68]
Serum albumin −3.53 [−11.89 to 4.84]
Cisplatin dose (per 5 mg/ml) −1.41 [−1.57 to 4.38]
Regular use drug
NSAIDs 7.63 [−1.75 to 17.02]
Mg for purgative 0.54 [−7.25 to 8.34]
Anorexia (grade 2 or more) −2.13 [−9.51 to 5.24]
Mg infusion −14.73 [−21.25 to −8.21]
Low volume hydration −3.40 [−11.33 to 4.53]
CI, confidential interval; PS, performance status; NSAIDs, non-steroid anti-Inflammatthat there may be a correlation between the availability of
Mg and vascular endothelial growth factor [23], and
in particular that Mg depletion may suppress tumor
cell proliferation and neoangiogenesis. Therefore, there
could be some concern that Mg supplementation might
promote tumor cell proliferation. However, previous pro-
spective clinical trials and retrospective studies have indi-
cated that Mg supplementation does not affect tumor
response to cisplatin-based chemotherapy [7,10,11]. At any
rate, the relationship between Mg depletion and tumor
response to chemotherapy will require further investigation.
The present study has some limitations. First, this
was a historical prospective cohort study and included a
relatively small number of patients. Second, while somee and multivariate analyses
Maltivariate
P value Coefficient [95% CI] P value
0.375 −1.58 [−3.74 to 0.58] 0.149
0.182 5.63 [−1.64 to 12.91] 0.127
0.087 3.34 [−4.82 to 11.49] 0.418
0.404 −1.28 [−9.14 to 6.59] 0.747
0.348 1.24 [−1.40 to 3.90] 0.35
0.109 2.98 [−5.25 to 11.21] 0.473
0.89 −3.67 [−10.10 to 2.76] 0.259
0.566 2.19 [−5.31 to 9.70] 0.562
<0.001 −15.28 [−21.99 to −8.57] <0.001
0.396 22.31 [9.16 to 35.46] 0.001
ory drugs; Mg for purgative, Magnesium containing medications for purgative.
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http://www.biomedcentral.com/2050-6511/15/70patients had consumed 2,000 ml of water on day 1 and
1,000 ml of water on days 2 and 3, the optimal amount of
fluid intake was not evaluated. Indeed, many previous
examinations of low-volume hydration involved oral
hydration on days 2 and 3 rather than infusion; however,
the effect of oral hydration has not yet been examined.
Third, no data on the levels of serum Mg levels was
available. It is known that serum hypomagnesemia reflects
Mg depletion, but serum Mg is only 1% of the total Mg
present in the body [24]. In some cases, levels of serum
Mg may not be decreased even in the presence of Mg
depletion. Cisplatin treatment is one such case, and Mg
supplementation is needed even in the absence of serum
hypomagnesemia. This renders it difficult to know the
optimal amount of Mg supplementation. Nonetheless, our
study revealed that even 8 mEq of Mg sulfate reduced
renal toxicity. Fourth, renal function in cisplatin chemo-
therapy was assessed only after the first or last cycle. The
renal damage by cisplatin may be cumulative. The know-
ledge of sCr in the following cycles would be important.
In our study, in the high-volume Mg- group, the median
value of sCr after the last cycle was significantly higher
than after the first cycle (p = 0.004) (data not shown). This
result suggests that the renal damage by cisplatin was
cumulative with every cycle in Mg- group. Thus, Mg
supplementation with high-volume hydration may have a
much greater impact on renal damage caused by cisplatin.Conclusion
High-volume hydration and Mg supplementation can
reduce the renal toxicity induced by cisplatin. Our
data also suggest that a low-volume Mg+ regimen can
be considered for patients with adequate renal function.
Further prospective clinical studies in a larger patient
population, including association with total body Mg levels
and optimization of Mg intake, along with correlations
between Mg depletion and tumor response to chemotherapy
should be performed.Additional files
Additional file 1: Cisplatin chemotherapy administered.
Additional file 2: The comparison between pre and end of sCr in
each group.
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